Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 30% during mid-day trading on Wednesday . The stock traded as high as C$0.15 and last traded at C$0.13. 430,289 shares changed hands during trading, a decline of 10% from the average session volume of 480,285 shares. The stock had previously closed at C$0.10.
Hemostemix Trading Up 30.0%
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a fifty day moving average price of C$0.10 and a 200-day moving average price of C$0.14. The company has a market cap of C$18.94 million, a P/E ratio of -3.79 and a beta of 0.20.
Insider Activity
In related news, Director Peter Alan Lacey purchased 200,000 shares of Hemostemix stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is currently owned by company insiders.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough
- Insider Trading – What You Need to Know
- Applied Digital’s Strategic AI Play Gains Momentum
- What is the Hang Seng index?
- Top 5 Stocks Hedge Funds Are Buying Right Now
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
